For moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients1

DEFY EXPECTATIONS

Challenge treatment
goals in RA

Exceptional access is already here. RINVOQ has achieved 99% preferred commercial coverage Exceptional access is already here. RINVOQ has achieved 99% preferred commercial coverage Exceptional access is already here. RINVOQ has achieved 99% preferred commercial coverage

RINVOQ met ALL primary (ACR20 or ACR50 at Week 12 or 14) and ranked secondary endpoints across clinical trials, with some achieving ACR20 as early as Week 1 in SELECT-BEYOND.1,3  
See results below

*Preferred means RINVOQ is placed on the plan's preferred formulary.
Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
Data on File, AbbVie Inc. May 2022

ACR=American College of Rheumatology; IR=intolerance or inadequate response; MTX=methotrexate; TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor

Join an upcoming educational speaker program webinar Join an upcoming educational speaker program webinar Join an upcoming educational speaker program webinar

RINVOQ (upadacitinib) met all primary and ranked secondary endpoints1,4

Primary Endpoint Results
(Week 12 or 14)

Primary Endpoint Results (Week 12/14) Primary Endpoint Results (Week 12/14) Primary Endpoint Results (Week 12/14)

SELECT-BEYOND: 27% RINVOQ 15 mg + csDMARD vs 11% Placebo + csDMARD1,3,†

SELECT‑BEYOND
(Study RA‑V):1,3

12‑week, randomized, double‑blind, placebo‑controlled study of 499 adult patients with moderate to severe RA who had an inadequate response or intolerance to bDMARDs.

SELECT‑EARLY
(Study RA‑I):1,5

48‑week, randomized, double‑blind, active comparator‑controlled study of 947 adult patients with moderate to severe RA who were MTX‑naïve.

SELECT‑
MONOTHERAPY (Study RA‑II):1,6

14‑week, randomized, double‑blind, active comparator‑controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX.

SELECT‑NEXT
(STUDY RA‑III)1,7

12‑week, randomized, double‑blind, placebo‑controlled study of 661 adult patients with moderate to severe RA who had an inadequate response to csDMARDs.

SELECT‑COMPARE
(Study RA‑IV):1,8

48‑week, randomized, double‑blind, active comparator‑controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX.

RINVOQ is a once-daily JAK inhibitor1

Durable remission, even without MTX3,6,9,10

Remission* & LDA rates with or without MTX at weeks 12 or 14 with response rates from 60 to 84 weeks in SELECT-BEYOND and SELECT-MONOTHERAPY, respectively

*Does not mean drug-free remission or complete absence of disease activity

Safety data from 18 clinical trials across 5 indications1,11-15,†

>10,500 patients in global clinical trials across US-approved indications, including pediatrics 12+ years in AD1,11-13,15,‡
>18,500 patient-years of exposure to RINVOQ 15 or 30 mg12,15-19,§
~5.5 years max. exposure beginning in RA (~3.5 yrs median) to RINVOQ 15 mg as of 6/30/2116,20,||

AbbVie's commitment to exceptional access and patient support

99% preferred national commercial coverage2,¶,#,** and 1:1 support to help patients start and stay on track with their prescribed treatment plan

Includes 6 RA phase 3 studies (SELECT-EARLY, SELECT-MONOTHERAPY, SELECT-NEXT, SELECT-COMPARE, SELECT-BEYOND, and SELECT-CHOICE); 2 PsA phase 3 studies (SELECT-PsA 1 and SELECT-PsA 2); 1 AS phase 2/3 study (SELECT-AXIS 1) and 1 AS phase 3 study (SELECT-AXIS 2); 4 AD phase 3 studies (MEASURE UP 1, MEASURE UP 2, AD UP, and HEADS UP); and 4 UC phase 3 studies (U-ACHIEVE Induction, U-ACCOMPLISH Induction, U-ACHIEVE Maintenance, and the long-term extension study).1,11-15
RA: RINVOQ 15 mg, upadacitinib 30 mg; PsA: RINVOQ 15 mg, upadacitinib 30 mg; AS: RINVOQ 15 mg; AD: RINVOQ 15 mg and RINVOQ 30 mg; UC: RINVOQ 15 mg, 30 mg, and 45 mg. RINVOQ 15 mg is the approved dose in RA, PsA, and AS; RINVOQ 15 mg and 30 mg are the approved doses in AD; RINVOQ 15 mg, 30 mg and 45 mg are the approved doses in UC.1,11-13,15,17
§Includes 12,259.5 patient-years in RA trials as of 06/2021, 2504.6 patient-years in PsA trials as of 06/2020, 2787.6 patient-years in AD trials as of 11/2020, 381.1 patient-years in UC trials as of 04/2021, and 577.3 patient-years in AS trials as of 11/2020 for SELECT-AXIS 1 and 08/2021 for SELECT-AXIS 2 study 1.12,15-19,21
||In PsA: ~3 years maximum exposure (~1.3 years median) to RINVOQ 15 mg as of 06/2020. In AS: ~2.3 years maximum exposure (~1.7 years median) to RINVOQ 15 mg as of 06/2020 (AS exposure data is from SELECT-AXIS 1).12,22
Formulary definitions: Preferred means RINVOQ is placed on the plan’s preferred formulary.
#National Commercial Formulary coverage under the pharmacy benefit as of May 2022.
**Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

ACR=American College of Rheumatology; CRP=C-reactive protein; csDMARDs=conventional synthetic disease-modifying antirheumatic drugs; HAQ-DI=health assessment questionnaire disability index; JAK=Janus kinase; mTSS=modified total Sharp score; MTX=methotrexate; TNFi=tumor necrosis factor inhibitor

RINVOQ™ COMPLETE

See how UPADAC Complete provides an exceptional access
and patient support experience